AHRQ Patient Safety Network ► Evaluating iatrogenic prescribing: development of an oncology-focused trigger tool.

AHRQ Patient Safety Network



Evaluating iatrogenic prescribing: development of an oncology-focused trigger tool.

Hébert G, Netzer F, Ferrua M, Ducreux M, Lemare F, Minvielle E. Eur J Cancer. 2015;51:427-435.

This study describes the development and validation of an oncology trigger tool, modeled after the Institute for Healthcare Improvement's Global Trigger Tool, to capture adverse drug events during cancer care. The final tool included 22 triggers and achieved high interrater reproducibility, but had only a modest 20% positive predictive value.

PubMed citation 
Available at 

Related Resources

STUDY

Chemotherapy safety and severe adverse events in cancer patients: strategies to efficiently avoid chemotherapy errors in in- and outpatient treatment.

Markert A, Thierry V, Kleber M, Behrens M, Engelhardt M. Int J Cancer. 2009;124:722-728.

STUDY

Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs.

Ranchon F, Salles G, Späth HM, et al. BMC Cancer. 2011;11:478.

STUDY

Is oral chemotherapy prescription safe for patients? A cross-sectional survey.

Bourmaud A, Pacaut C, Melis A, et al. Ann Oncol. 2014;25:500-504.

STUDY

Improving cancer patient care with combined medication error reviews and morbidity and mortality conferences.

Ranchon F, You B, Salles G, et al. Chemotherapy. 2014;59:330-337.

View all related resources...